Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | EEF2K | O00418 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 5/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.33 |
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491947 | 0.89 | BACE1 (0.37) | OPRM1OPRL1BACE1BACE2OPRD1 | |
| SCHEMBL3892756 | 0.89 | BACE1 (0.37) | OPRM1OPRL1BACE1BACE2OPRD1 | |
| SCHEMBL3492314 | 0.84 | HPGDS (0.34) | EEF2KBACE1BACE2HPGDS | |
| SCHEMBL3887599 | 0.84 | HPGDS (0.34) | EEF2KBACE1BACE2HPGDS | |
| SCHEMBL13359099 | 0.82 | OPRM1 (0.37) | OPRM1OPRL1BACE1BACE2OPRK1 | |
| SCHEMBL764691 | 0.82 | ADORA3 (0.40) | OPRM1OPRL1BACE1BACE2OPRD1 | |
| SCHEMBL760030 | 0.81 | BACE1 (0.34) | OPRM1OPRL1BACE1BACE2OPRD1 | |
| SCHEMBL755429 | 0.81 | BACE1 (0.34) | OPRM1OPRL1BACE1BACE2OPRD1 | |
| SCHEMBL755862 | 0.81 | BACE1 (0.34) | OPRM1OPRL1BACE1BACE2OPRD1 | |
| SCHEMBL10293318 | 0.81 | BACE1 (0.34) | OPRM1OPRL1BACE1BACE2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293759-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293759-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme, Corp. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2091328-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-18 | — | — | US | disclosed |
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069419-A1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, APP | OPRM1 4499/4885OPRL1 2101/4885EEF2K 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.